Why Zoetis stock is back in focus after fresh activism and recent earnings
Zoetis (ZTS) is drawing attention after reporting organic revenue and adjusted net income growth. The company is also facing a new shareholder rights proposal that management is urging investors to vote against at the upcoming annual meeting.
See our latest analysis for Zoetis.
The fresh activism around shareholder rights arrives after a weaker run for investors, with a 1-year total shareholder return of 17.19% and a 3-year total shareholder return of 28.46%. Recent 90-day share price returns of 5.65% suggest fading near term momentum, even as operational updates and conference appearances keep Zoetis in the spotlight.
If this mix of earnings news and governance debate has you reassessing your watchlist, it could be a good time to widen the search and check out 36 healthcare AI stocks
Zoetis now trades around US$119.99, with annual revenue of US$9.47b and net income of US$2.67b, plus an indicated intrinsic discount and gap to analyst targets. Is this weakness a chance to buy, or is the market already pricing in future growth?
Most Popular Narrative: 20.5% Undervalued
Zoetis' most followed narrative pegs fair value at $151.00, compared with the last close at $119.99. This frames a valuation gap built on detailed growth and margin assumptions.
Ongoing innovation and accelerated R&D output, with expectations for a major new product approval in a key market every year over the next few years, positions Zoetis to expand addressable markets, launch higher-margin products, and protect market share, positively impacting organic revenue growth and net margins.
Want to see what earnings, revenue mix, and margin trajectory have to look like for that valuation to hold up? The narrative leans on a specific growth runway, rising profitability, and a premium future earnings multiple that goes well beyond the sector norm.
Result: Fair Value of $151.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story can change quickly if osteoarthritis products face ongoing safety concerns or if competition in parasiticides and dermatology puts unexpected pressure on pricing and margins.
Find out about the key risks to this Zoetis narrative.
Another Angle on Valuation
The earlier fair value of $151.00 leans on detailed growth and margin assumptions, but the current P/E of 18.9x tells a slightly different story. It sits above the US Pharmaceuticals industry at 16.9x, yet below the peer average of 22.4x and its own fair ratio of 20.9x, which points to some valuation tension for investors to weigh.
To make sense of that gap, it helps to see how the valuation stacks up in a simple side by side comparison, and what the fair ratio implies about where the market could move over time, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mix of optimism and concern across this article, it makes sense to move quickly, review the full data set, and decide where you stand based on the company's 5 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Zoetis is on your radar, do not stop there, you could miss other opportunities that match your goals and risk comfort on Simply Wall Street.
- Target dependable income by reviewing companies in the 11 dividend fortresses that may suit investors who want yields backed by solid fundamentals.
- Hunt for quality at a sensible price using the 62 high quality undervalued stocks to spot stocks where fundamentals and valuation screens currently align.
- Prioritise resilience by scanning the 73 resilient stocks with low risk scores if you want ideas with steadier risk profiles for the core of your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com